Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q2 EPS of ($1.16), $0.09 better than the analyst estimate of ($1.25). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $4.83 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip
• Northland lifts Semtech rating, sees connectivity as the AI bottleneck
• Intuit (INTU) PT Lowered to $370 at Freedom Broker